King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more ...

Chemotherapy may soon take a backseat. Experts say targeted therapies—drugs that attack cancer at the genetic level—are ...

Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...

The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study ( NCT05898399 ), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients ...

ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's ...

When pembrolizumab was added to paclitaxel with or without bevacizumab in platinum-resistant ovarian cancer, significant ...